S5, Ep 15- Clinical Trials and Management of Chronic Pain Conditions: The Importance of Represent...

Описание: In this episode, our hosts are joined by Dr. Titilola Falasinnu, Assistant Professor at the Stanford School of Medicine, epidemiologist, and pain scientist. Dr. Falasinnu shares about the importance of increasing diversity in lupus clinical trials, her research supporting the experience of patients with chronic pain, and the need to address the unique needs of autoimmune patients.


"We urgently need guidelines for the management of chronic pain… to address the individual needs of the patients from a biopsychosocial perspective, which is where the physical and emotional well-being of the patients are prioritized. So this requires an interdisciplinary approach where multiple specialties work in concert with rheumatologists to address the complex needs of patients with chronic pain conditions,” says Dr. Falasinnu.


Among the highlights in this episode:


1:13: 2022 marked a record for Affordable Care Act enrollment with about 16 million people having enrolled in the health insurance platform


2:05: The CDC expands airport screening: All air passengers 2 years of age and older originating from China will be required to get a COVID-19 test no more than two days before their departure, regardless of their vaccination status


3:55: Dr. Falasinnu elaborates on her career and what led to her research at the Stanford School of Medicine


5:55: Dr. Falasinnu shares the personal story behind her journey to becoming a lupus researcher


6:51: “In 2016, we did a review of the representation of racial minorities in lupus trials. We estimated that black patients comprise about 43% of lupus patients in the United States. However, black patients comprise only 14% of trial participants in lupus, and black representation actually dropped during the study period from 20%... to 10%, between 2012 and 2017,” says Dr. Falasinnu


7:35: “The issues of the lack of diversity in clinical trials is not unique to rheumatology, and we see it in cancer and cardiovascular disease trials as well,” says Dr. Falasinnu


8:48: Dr. Falasinnu shares how we can adapt traditional trial recruitment frameworks while acknowledging the challenge of engaging the lupus patient community as a whole


9:53: “Life with children can be very busy, and schedules of parents may not permit the addition of a clinical trial. I've been there,” says Dr. Falasinnu


11:05: Dr. Falasinnu discusses the study she worked on that aimed at estimating the burden of chronic overlapping pain conditions in patients with autoimmune rheumatic diseases


14:08: What health and patient advocacy mean to Dr. Falasinnu


16:39: What our hosts learned from this episode


Contact Our Hosts


Steven Newmark, Director of Policy at GHLF: [email protected] (mailto:[email protected])


Zoe Rothblatt, Associate Director, Community Outreach at GHLF: [email protected] (mailto:[email protected])


We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to [email protected] (mailto:[email protected])


Catch up on all our episodes on our website or on your favorite podcast channel.


See omnystudio.com/listener (https://omnystudio.com/listener) for privacy information.